Can XOMA's Late-Stage Pipeline Finally Justify the Royalty Model?

XOMA Royalty Corporation reports Q1 2026 earnings on May 19, 2026, with analysts expecting $0.19 per share on the heels of a volatile 2025 that saw the biotech royalty aggregator swing from massive beats to a sharp miss. With the company adding 22 assets to its portfolio last year and 14 programs now in registrational studies, investors will be watching whether growing commercial royalty streams can deliver the consistent cash flow management has promised—or if Q1 marks another unpredictable quarter for this high-variance story.

Part 1: Earnings Preview

XOMA Royalty Corporation operates as a biotech royalty aggregator, generating revenue from royalties, milestones, and commercial payments tied to a diversified portfolio of biopharmaceutical assets. The company does not develop drugs itself but instead acquires economic interests in therapies developed by others, creating a leveraged bet on the success of multiple clinical and commercial programs.

XOMA reports Q1 2026 results on May 19, 2026, with the consensus estimate calling for $0.19 per share from three analysts. The company most recently reported Q4 2025 earnings of $0.12 per share, beating estimates by 192%. Compared to the same quarter last year (Q1 2025), when XOMA earned $0.06 per share, the current estimate implies year-over-year growth of 217%—a dramatic acceleration that reflects the company's expanding commercial royalty base.

Three key themes define this earnings story:

Portfolio Expansion and Diversification: XOMA added 22 assets and two platform technologies to its portfolio in 2025, deploying $25 million in capital to broaden its revenue streams. Management has emphasized that 14 programs are now in registrational studies, setting up multiple regulatory catalysts in 2026 and beyond. Investors will be watching whether this aggressive expansion is translating into tangible near-term revenue growth or if the benefits remain years away.

Commercial Royalty Momentum: Full-year 2025 royalties and commercial payments totaled $33.6 million, with key contributors including VABYSMO (faricimab-svoa) and OJEMDA (tovorafenib). The company achieved positive cash flow from operations for the first time and returned $16 million to shareholders through buybacks. The question for Q1 is whether this commercial momentum is accelerating or if growth is lumpy and milestone-dependent.

Earnings Volatility and Predictability: XOMA's recent earnings history has been wildly erratic, with Q2 2025 delivering a 500% beat followed by Q3's 1,650% miss. This volatility reflects the milestone-driven nature of the business, where large one-time payments can swing results dramatically. Analysts will be looking for signs that the growing base of commercial royalties is smoothing out this volatility and making earnings more predictable.

CEO Owen Hughes has stated that the company expects "growing free cash flow in 2027 and beyond" as registrational programs advance, but near-term visibility remains limited. Analysts are divided on the timing and magnitude of this inflection, with estimates for Q1 ranging from a loss of $0.16 to earnings of $0.50 per share—a massive spread that underscores the uncertainty around milestone timing and royalty ramp rates.

Part 2: Historical Earnings Performance

XOMA's earnings history over the past four quarters reveals extreme volatility driven by the milestone-dependent nature of its royalty business. The company has beaten estimates in three of the last four quarters, but the magnitude and direction of surprises have been wildly inconsistent.

Q1 2025 delivered a 123% beat ($0.06 actual vs. -$0.26 estimate), followed by an extraordinary 500% beat in Q2 2025 ($0.48 vs. -$0.12 estimate)—likely driven by large milestone payments. However, Q3 2025 saw a dramatic reversal with a 1,650% miss (-$0.35 vs. -$0.02 estimate), suggesting either a one-time charge or the absence of expected milestone payments. Q4 2025 rebounded with a 192% beat ($0.12 vs. -$0.13 estimate), returning to positive territory.

The pattern suggests that while XOMA has generally outperformed low analyst expectations, the business model produces highly unpredictable quarterly results. The swings appear to correlate with the timing of milestone payments and regulatory events rather than steady commercial royalty growth. Investors should expect continued volatility until the commercial royalty base becomes large enough to smooth out the impact of individual milestone events.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

XOMA typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around XOMA earnings shows significant volatility, with an average absolute Day 0 move of 6.02% and Day +1 move of 3.26%. The stock has exhibited particularly dramatic reactions in recent quarters: May 2025 saw a 10.89% Day 0 surge followed by a -2.73% Day +1 reversal, while August 2025 delivered a 14.40% Day 0 spike that gave back ground the next session. The most recent report in March 2026 was relatively muted with a 1.30% Day 0 gain and 5.16% Day +1 follow-through.

The data suggests XOMA tends to see its largest moves on Day 0 (anticipation) rather than Day +1 (reaction), though intraday ranges remain elevated in both sessions—averaging 7.28% on Day 0 and 6.12% on Day +1. Investors should prepare for potential swings of 5–10% in either direction, with the magnitude likely depending on whether the company reports significant milestone payments or provides updated guidance on its pipeline catalysts.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.59% expected move for the June expiration cycle, which is notably more conservative than XOMA's average historical Day 0 move of 6.02% and well below the 7.28% average intraday range on earnings day. This suggests options traders may be underpricing near-term volatility, particularly given the stock's history of double-digit swings around milestone-driven surprises.

Part 3: What Analysts Are Saying

Analyst sentiment on XOMA has deteriorated over the past month, with the average recommendation falling from 4.33 (Strong Buy) to 3.67 (between Hold and Buy). The current consensus includes 2 Strong Buy ratings and 4 Hold ratings, down from 4 Strong Buys and 2 Holds a month ago—indicating some analysts have grown more cautious heading into the Q1 report.

The average price target stands at $44.50, implying 6.9% upside from the current price of $41.64. Targets range from a low of $39.00 (6.3% downside) to a high of $50.00 (20.1% upside), reflecting divergent views on the timing and magnitude of XOMA's royalty growth inflection. The recent downgrade activity suggests some analysts may be taking a wait-and-see approach, wanting to see evidence that the company's portfolio expansion is translating into consistent revenue growth before reaffirming more bullish stances.

The shift from Strong Buy to Hold ratings among some analysts likely reflects concerns about near-term earnings predictability and the wide range of Q1 estimates ($-0.16 to $0.50), which underscores uncertainty around milestone timing. However, the consensus still leans positive, with the average target implying modest upside and no sell ratings in the mix.

Part 4: Technical Picture

XOMA enters earnings with strong technical momentum, trading at $41.64 and sitting above its 20-day ($40.94), 50-day ($35.67), 100-day ($30.88), and 200-day ($32.00) moving averages. The stock is slightly below its 5-day ($41.79) and 10-day ($41.69) averages, suggesting minor near-term consolidation after a sustained rally.

The Barchart Technical Opinion shows an 88% Buy signal, unchanged from last week but significantly improved from 56% Buy a month ago. This strengthening reflects the stock's breakout above key moving averages and sustained upward momentum through May.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates strong near-term momentum heading into the earnings release
• Medium-term (100% Buy): Equally strong intermediate-term signal suggests the uptrend is well-established across multiple timeframes
• Long-term (50% Buy): Moderate bullish reading reflects a more cautious longer-term outlook, likely due to the stock's historical volatility and uncertain earnings trajectory

Trend Characteristics: The combination of Strong strength and Average direction suggests XOMA is in a powerful uptrend but without extreme momentum that might signal an overbought condition—a relatively balanced setup for an earnings event.

The technical setup is broadly supportive heading into earnings, with the stock trading well above all major moving averages and showing coordinated bullish signals across short- and medium-term timeframes. The 50-day moving average at $35.67 has provided strong support during the recent rally, while the stock's position just below its 5-day and 10-day averages suggests it has paused rather than reversed. Key resistance likely sits near $43.55 (the options market's upper expected move boundary), while support should emerge around $39.73 (lower boundary) and more firmly at the 20-day average of $40.94. The technical picture favors the bulls, but the long-term signal's moderation to 50% Buy serves as a reminder that XOMA's volatility can quickly reverse gains if results or guidance disappoint.